Discover the best biotech ETFs to diversify your portfolio, gain exposure to cutting-edge biotech innovations, and reduce risk in a volatile sector.

Biotech ETFs can help investors capitalize on health care innovation while avoiding the boom-or-bust nature of individual ...

A smart beta exchange traded fund, the First Trust NYSE Arca Biotechnology ETF (FBT) debuted on 06/19/2006, and offers broad exposure to the Health Care ETFs category of the market. What Are Smart ...

PJP delivers lower volatility and higher income with concentrated pharma exposure, while XBI offers broader biotech growth at ...

PJP delivered stronger 5-year returns with lower volatility, while FBT offers broader biotech exposure at a slightly cheaper ...

Biotech is having a moment, and the numbers are hard to ignore. The SPDR S&P Biotech ETF (NYSEARCA:XBI) climbed 17.27% over ...

From broad domestic exposure to global pharma and biotech, these funds cover the healthcare sector's main themes.

Established pharmaceutical giants have delivered lower volatility and higher income than clinical-stage biotech exposure over the past five years.

FHLC is the far cheaper option for long-term investors, charging an expense ratio of just 0.08% compared to BBH's 0.35%. FHLC also pays a higher trailing dividend yield of 1.40%, nearly 0.9 percentage ...

Amid the trying circumstances in the market right now, investors may be well served to target the best biotech ETFs to buy. Fundamentally, these exchange-traded funds benefit from permanent relevance.